Develops an investigational treatment for alcohol use disorder in patients with specified genetic subgroups.
10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 5, 2026
8-K, filed Oct 28, 2026
On October 28, 2026, stockholders approved the conversion of the Company’s Series A preferred stock issued in connection with the June 2026…View ↗
Purnovate leaves the portfolio
The earlier report described Purnovate's adenosine drug-discovery platform as part of its portfolio; the latest centers on its lead addiction-treatment candidate and says Purnovate's assets and business were sold.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 5, 2026In January 2021, we expanded our portfolio in the field of addiction with the acquisition of Purnovate, LLC via a merger into our wholly…View ↗
From commercialization to clinical development
The earlier report described a focus on commercializing its lead candidate in the U.S. and Europe; the latest describes completing clinical development, primarily for U.S. regulatory requirements, with Europe and the UK secondary.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction…View ↗
We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction…View ↗
Loading...